A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug
Leflunomide is one of the most promising disease-modifying antirheumatic drug now in clinical trials for the treatment of rheumatoid arthritis. Metabolic studies have indicated that leflunomide is rapidly processed in vivo to an active metabolite, A771726 (2). To identify the chemical characteristics necessary for the immunosuppressive activity of 2, configurational and conformational studies were carried out on the latter and its inactive analogues (ethyl 3-hydroxy-2-((4-(trifluoromethyl)phenyl)carbamoyl)but-2-enoate, 3a, and 3-hydroxy-2-nitro-N-(4-(trifluoromethyl)phenyl)but-2-enamide, 3b). These studies suggested that the pharmacophore responsible for the immunosuppressive activity of 2 is a beta-keto amide with the enolic hydroxy group cis to the amidic moiety. To verify this hypothesis, a new class of immunosuppressive agents was designed and synthesized. Their testing in vitro and in vivo identified compounds which were more potent than both leflunomide and 2 and above all confirmed our hypothesis as to the key structural and chemical determinants for the immunosuppressive properties of 2 and our compounds.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
1997 |
---|---|
Erschienen: |
1997 |
Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
---|---|
Enthalten in: |
Journal of medicinal chemistry - 40(1997), 13 vom: 20. Juni, Seite 2011-6 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Bertolini, G [VerfasserIn] |
---|
Themen: |
1C058IKG3B |
---|
Anmerkungen: |
Date Completed 07.08.1997 Date Revised 03.12.2021 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM091626927 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM091626927 | ||
003 | DE-627 | ||
005 | 20231222085108.0 | ||
007 | tu | ||
008 | 231222s1997 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0306.xml |
035 | |a (DE-627)NLM091626927 | ||
035 | |a (NLM)9207942 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Bertolini, G |e verfasserin |4 aut | |
245 | 1 | 2 | |a A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug |
264 | 1 | |c 1997 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 07.08.1997 | ||
500 | |a Date Revised 03.12.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Leflunomide is one of the most promising disease-modifying antirheumatic drug now in clinical trials for the treatment of rheumatoid arthritis. Metabolic studies have indicated that leflunomide is rapidly processed in vivo to an active metabolite, A771726 (2). To identify the chemical characteristics necessary for the immunosuppressive activity of 2, configurational and conformational studies were carried out on the latter and its inactive analogues (ethyl 3-hydroxy-2-((4-(trifluoromethyl)phenyl)carbamoyl)but-2-enoate, 3a, and 3-hydroxy-2-nitro-N-(4-(trifluoromethyl)phenyl)but-2-enamide, 3b). These studies suggested that the pharmacophore responsible for the immunosuppressive activity of 2 is a beta-keto amide with the enolic hydroxy group cis to the amidic moiety. To verify this hypothesis, a new class of immunosuppressive agents was designed and synthesized. Their testing in vitro and in vivo identified compounds which were more potent than both leflunomide and 2 and above all confirmed our hypothesis as to the key structural and chemical determinants for the immunosuppressive properties of 2 and our compounds | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Aniline Compounds |2 NLM | |
650 | 7 | |a Crotonates |2 NLM | |
650 | 7 | |a Hydroxybutyrates |2 NLM | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
650 | 7 | |a Isoxazoles |2 NLM | |
650 | 7 | |a Nitriles |2 NLM | |
650 | 7 | |a Prodrugs |2 NLM | |
650 | 7 | |a Toluidines |2 NLM | |
650 | 7 | |a teriflunomide |2 NLM | |
650 | 7 | |a 1C058IKG3B |2 NLM | |
650 | 7 | |a Leflunomide |2 NLM | |
650 | 7 | |a G162GK9U4W |2 NLM | |
700 | 1 | |a Aquino, M |e verfasserin |4 aut | |
700 | 1 | |a Biffi, M |e verfasserin |4 aut | |
700 | 1 | |a d'Atri, G |e verfasserin |4 aut | |
700 | 1 | |a Di Pierro, F |e verfasserin |4 aut | |
700 | 1 | |a Ferrario, F |e verfasserin |4 aut | |
700 | 1 | |a Mascagni, P |e verfasserin |4 aut | |
700 | 1 | |a Somenzi, F |e verfasserin |4 aut | |
700 | 1 | |a Zaliani, A |e verfasserin |4 aut | |
700 | 1 | |a Leoni, F |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of medicinal chemistry |d 1963 |g 40(1997), 13 vom: 20. Juni, Seite 2011-6 |w (DE-627)NLM000006602 |x 1520-4804 |7 nnns |
773 | 1 | 8 | |g volume:40 |g year:1997 |g number:13 |g day:20 |g month:06 |g pages:2011-6 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 40 |j 1997 |e 13 |b 20 |c 06 |h 2011-6 |